Originating countries and manufacturers of crizotinib

The development process of Crizotinib marks the transformation of lung cancer treatment from traditional chemotherapy to molecular targeted therapy. The drug was developed by Pfizer Inc. and was first approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of ALK-positive non-small cell lung cancer (NSCLC). As an original drug, its launch has not only changed the treatment prognosis of some lung cancer patients, but also promoted the global popularization of detection of driver gene mutations such as ALK and ROS1.

Pfizer, as a world-renowned multinational pharmaceutical company, has a strong R&D, production and quality control system. The original research and production sites of crizotinib are mainly located in the United States and Europe. With strict GMP standards and a complete supply chain, the stability of drug quality and the continuity of global supply are guaranteed. With the expiration of drug patents and the adjustment of generic drug policies in various countries, generic versions with qualified quality have appeared in some countries and regions. However, the original drugs still maintain high standards of clinical trust in terms of drug consistency, clinical trial data and pre-market evaluation.

In China, Pfizer's crizotinib is marketed under the trade name "XALKORI" and is sold through official channels. The main dosage forms are 250mg and 200mg capsules, and the packaging specifications are usually 60 capsules/box. The efficacy and safety of original drugs have been clinically verified for a long time, and their production processes, raw material sources and testing standards strictly comply with international standards. This is also an important reason why original drugs are recommended first in clinical practice when conditions permit. Currently, although some generic drugs are being applied for or launched in the domestic market, the original Pfizer crizotinib still occupies a dominant position in the field of targeted treatment of lung cancer.

Reference materials:https://go.drugbank.com/drugs/DB08865